LUNG PENETRATION OF CASPOFUNGIN INTO EPITHELIAL LINING FLUID - Caspofungin in epithelial lining fluid

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-004107-20-AT

Enrollment

Registered

2007-10-15

Start date

2007-10-23

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasma and ELF concentrations of Caspofungin will be measured in patients requiring treatment with Cancidas (Caspofungin) for fungal infection (proven or suspected)

Interventions

Trade Name: Cancidas Product Name: Cancidas Pharmaceutical Form: Concentrate for solution for infusion CAS Number: 179463173 Other descriptive name: CASPOFUNGIN ACETATE

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Indication for treatment with caspofungin Indication for bronchoalveolar lavage Age above 18 years Are the trial subjects under 18? Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: lacking indication/contraindication for caspofungin lacking indication/contraindication for bronchoalveolar lavage lacking consent pregnancy age below 18 years

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine concentrations of caspofungin in the epithelial lining fluid (ELF) compared to the plasma concentration of caspofungin in patients with fungal infection.;Secondary Objective: to determine lung penetration of caspofungin administered in patients with fungal infection ;Primary end point(s): Concentration of caspofungin in epithelial lining fluid Concentration of caspofungin in plasma penetration of caspofungin into the lung (C elf/C plasma)	—

Measure

Time frame

Main Objective: To determine concentrations of caspofungin in the epithelial lining fluid (ELF) compared to the plasma concentration of caspofungin in patients with fungal infection.;Secondary Objective: to determine lung penetration of caspofungin administered in patients with fungal infection ;Primary end point(s): Concentration of caspofungin in epithelial lining fluid Concentration of caspofungin in plasma penetration of caspofungin into the lung (C elf/C plasma)

—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026